More Patient Education, Communication May Improve Myeloproliferative Neoplasm Care

Share this content:
More patient education and patient-physician communication among those with myeloproliferative neoplasms may improve care and satisfaction.
More patient education and patient-physician communication among those with myeloproliferative neoplasms may improve care and satisfaction.

More patient education and patient-physician communication among those with myeloproliferative neoplasms (MPNs) may improve care and satisfaction, according to a study published in Cancer.1

Researchers led by Ruben Mesa, MD, of the Mayo Clinic Cancer Center in Scottsdale, Arizona, conducted a survey that included 813 patients who had MPNs, polycythemia vera (PV), or essential thrombocythemia (ET), as well as 457 hematologist/oncologist respondents who treated patients diagnosed with these conditions.

It was found that a greater proportion of physician respondents used prognostic risk classifications in contrast with patient recollections.

Whereas most physician respondents reported symptom assessments that would include asking a full list of symptoms, patient respondents reported that their assessments were less specific.

Many patient respondents did not recognize that symptoms were related to MPN, with about a half or more not believing that difficulty sleeping was because of MPN. More than a third of patient respondents reported that they were not “very satisfied” with the overall management/communication of their physicians.

RELATED: Germline Variants Found in Half of Evaluated Patients With Sarcoma

Compared to patient respondents, physicians underestimated the proportion of patients who had symptomatic PV or ET at diagnosis, and the researchers noted a disparity in treatment goals between the 2 groups.

Reference

  1. Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. 2016 Sep 30. doi: 10.1002/cncr.30325 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters